Patent intelligence · US
US 9205044
Aqueous pharmaceutical preparation comprising roflumilast
Aqueous pharmaceutical preparation comprising roflumilast
Patent details — US 9205044
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 8, 2015
- Expiration
- Dec 3, 2035
- Applicant
- TAKEDA GMBH
- Claims
- 2
- CPC classes
- A61K, A61K31/44, A61K47/10, A61K47/12
Quick answer
US 9205044 (Aqueous pharmaceutical preparation comprising roflumilast) is held by TAKEDA GMBH. Status: granted. Granted Dec 8, 2015. Expires Dec 3, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TAKEDA GMBH
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K31/44, A61K47/10, A61K47/12, A61K47/14, A61K9/0019
More from TAKEDA GMBH
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 9205044?
US 9205044 (Aqueous pharmaceutical preparation comprising roflumilast) is held by TAKEDA GMBH. Status: granted. Granted Dec 8, 2015. Expires Dec 3, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9205044?
TAKEDA GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 9205044 expire?
Our index shows an expiration date of Dec 3, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.